Author/Authors :
ZAROGOULIDIS, Paul Pulmonary Department, Oncology Unit - G. Papanikolaou General Hospital - Aristotle University of Thessaloniki, Thessaloniki, Greece , LAMPAKI, Sofia Pulmonary Department, Oncology Unit - G. Papanikolaou General Hospital - Aristotle University of Thessaloniki, Thessaloniki, Greece , CHINELIS, Panos Pulmonary Department, Oncology Unit - G. Papanikolaou General Hospital - Aristotle University of Thessaloniki, Thessaloniki, Greece , LAZARIDIS, George Oncology Department - G. Papageorgiou University General Hospital, Thessaloniki, Greece , BAKA, Sofia Oncology Department - Interbalkan European Medical Center Thessaloniki, Greece , RAPTI, Aggeliki Pulmonary Department - Sotiria Hospital of Chest Diseases, Athens, Greece
Abstract :
Lung cancer is still diagnosed during the advanced stage of the disease and most patients do not have the opportunity for surgical treatment, despite the new diagnostic equipment that has been made available in recent years, such as the radial and linear endobronchial ultrasound (EBUS) and electromagnetic fiberoptic bronchoscopy. However, novel targeted therapies with second generation tyrosine kinase inhibitors and immunotherapy are available. In this commentary, we will focus on eye metastasis after initiation of tyrosine kinase inhibitors due to epidermal growth factor mutation of lung cancer adenocarcinoma.
